Original Research

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Falmata B. Shettima, Musa A. Wakil, Taiwo L. Sheikh, Mohammed Abdulaziz, Ibrahim A. Wakawa, Omeiza Beida
South African Journal of Psychiatry | Vol 30 | a2133 | DOI: https://doi.org/10.4102/sajpsychiatry.v30i0.2133 | © 2024 Falmata B. Shettima, Musa A. Wakil, Taiwo L. Sheikh, Mohammed Abdulaziz, Ibrahim A. Wakawa, Omeiza Beida | This work is licensed under CC Attribution 4.0
Submitted: 22 June 2023 | Published: 01 February 2024

About the author(s)

Falmata B. Shettima, Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Musa A. Wakil, Department of Mental Health, Faculty of Psychiatry, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Taiwo L. Sheikh, Department of Mental Health, Faculty of Psychiatry, Ahmadu Bello University Zaria, Kaduna, Nigeria
Mohammed Abdulaziz, Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital Kaduna, Kaduna, Nigeria
Ibrahim A. Wakawa, Department of Mental Health, Faculty of Psychiatry, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria
Omeiza Beida, Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital Kaduna, Kaduna, Nigeria

Abstract

Background: Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician’s insufficient knowledge.

Aim: The study aimed to evaluate the patterns and correlates of hyperprolactinemia among patients with schizophrenia on antipsychotic medications.

Setting: The study was conducted in a psychiatric facility in Maiduguri, Northeastern Nigeria.

Methods: A total of 209 patients with schizophrenia were evaluated through a cross-sectional design and assayed for serum prolactin with ELISA Kits. Frequencies and percentages were tabulated for categorical variables. Variables with significant associations with hyperprolactinaemia on chi-square (p < 0.05) were subjected to logistic regression analysis.

Results: The prevalence of hyperprolactinaemia was 45.9% in all patients on antipsychotic medication. The prevalence because of the use of typical and atypical antipsychotics was 51.5% and 25.0%, respectively. Hyperprolactinaemia was significantly associated with typical antipsychotics (β = 0314, p = 0.002), high overall drug dosage (β = 2.340, p = 0.003), high-dose typical antipsychotics (β = 3.228, p = 0.000), twice daily dosing frequency (β = 2.751, p = 0.001) and polypharmacy (β = 1.828, p = 0.0024).

Conclusion: The findings support that patients on typical, high-dose antipsychotic medications and polypharmacy have a high prevalence of hyperprolactinaemia. As hyperprolactinaemia is often undetectable, screening and patient psycho-education on the significance of the signs and symptoms of hyperprolactinaemia is required for necessary clinical intervention.

Contribution: The study provides evidence for the rational use of antipsychotic medications in sub-Saharan Africa.

 


Keywords

hyperprolactinaemia; antipsychotics; prolactin; schizophrenia; Nigeria

Sustainable Development Goal

Goal 3: Good health and well-being

Metrics

Total abstract views: 1065
Total article views: 542


Crossref Citations

No related citations found.